Study numberTumour typeStatusPhaseDetailsContact
1.2021Any Anthracycline sensitive cancer which has an injectable tumourOpen and recruiting1Open-Label Study of SQ3370 in Patients with Advanced Solid Tumours Ph: 08 8359 2565 Fax: 08 7123 6170
2.2021Early stage Breast cancer - for hormone blockadeOpen and recruiting3Randomized, open-label, study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patient with Estrogen receptor positive, HER2 negative Early Breast Cancer - LiDERA Ph: 08 8359 2565 Fax: 08 7123 6170
3.2021Metastatic Prostate cancer - which is hormone responsiveOpen and recruiting3Randomised, placebo controlled, double blind study of Darolutamide plus androgen deprivation therapy (ADT) VS ADT in subject with metastatic hormone sensitive prostate cancer (mHSPC) - Ph: 08 8359 2565 Fax: 08 7123 6170
4.2022Any Her2 positive cancerOpen and recruiting1A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 (HER2 blockade) in subjects with previously treated advanced HER2-positive solid Ph: 08 8359 2565 Fax: 08 7123 6170
5.2022Metastatic Breast cancer - ER/PR positive, Her2 negativeOpen and recruiting1A Phase I/II Open-label, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic Hormone Receptor (HR)-positive, HER2-negative breast cancer  OLEMA Ph: 08 8359 2565 Fax: 08 7123 6170
6.2022Metastatic Lung cancer - second line or moreOpen and recruiting3A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Ph: 08 8359 2565 Fax: 08 7123 6170


Clinical trials are a critical bridge between research discovery and improved treatment and care.

Clinical trials assess the success rate of treatments in humans. Access to research discoveries mean cancer patients can participate in cutting-edge treatments and contribute to learnings.

The CRSA alliance is developing programs to address the areas of greatest need and significant gaps in clinical trial activity.

The multi-pronged approach will provide cohesive delivery of:

  • increased clinical trial capability to underserved areas
  • broadened clinical trial access to patients across Victoria
  • advanced metrics to progress measurement and evaluation of clinical trials



See RESOURCES – Clinical Trials